Cardiovascular Risk Reduction in T2DM: Applying Trial Data in Cardiology Practice

Format: Webcourse

Credit(s): 1.00 (60 min)

Release Date: May 24, 2019

Expiration Date: May 24, 2020

Credit Type(s):

CME / AMA PRA Category 1 Credit™

PROGRAM OVERVIEW

Cardiovascular disease (CVD) is a leading cause of death in patients with type 2 diabetes mellitus (T2DM). The presence of diabetes also markedly increases the risk of 1-year adverse clinical outcomes (hospitalizations, mortality) in outpatients with heart failure. Multiple clinical trials have been undertaken to address critical issues in the management of CVD and T2DM. Trial findings have shown that the use of newer antihyperglycemic agents can reduce the rate of major cardiovascular events, including heart failure.

Cardiovascular Risk Reduction in T2DM: Applying Trial Data in Cardiology Practice will explore the burden of CVD in patients with T2DM, and outline the results from cardiovascular outcomes trials exploring the benefits and risks of antihyperglycemic agents in reducing CVD in patients with T2DM.

AGENDA

Welcome and Introduction
Recognize the Risk and Burden of CVD in Patients with T2DM
Cardiovascular Outcomes Trials: Benefits of Antihyperglycemic Agents on Reducing CVD
Applying the Data to Clinical Practice
Concluding Remarks

TARGET AUDIENCE

The intended audience for this educational activity includes cardiologists who manage cardiovascular risk and existing CVD in patients with T2DM.

EDUCATIONAL OBJECTIVES

This program is designed to address ACGME and IOM competencies, including delivering patient-centered care, practicing evidence-based medicine, and focusing on quality improvement.

At the conclusion of this activity, participants should be able to:

Recognize the burden of cardiovascular risk and established CVD in patients with T2DM
Assess the benefits observed in cardiovascular outcomes trials demonstrating reductions in CVD risk in patients with T2DM, along with appropriate applications in clinical practice

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about accreditation of this activity, please email: cpdsupport@health.usf.edu.

FACULTY

Prakash Deedwania, MD, FACC, FAHA, FACP, FASH, FHFSA, FESC
Professor of Medicine
UCSF School of Medicine
San Francisco, CA

Prakash Deedwania, MD, FACC, FAHA, FACP, FASH, FHFSA, FESC is one of the most recognizable figures in the fields of lipid disorders, hypertension, heart failure, ischemic heart disease, rhythm disorders, and preventive cardiology. He is Professor of Medicine at the University of California–San Francisco (UCSF) School of Medicine in Fresno, CA. Dr. Deedwania is also Director of Cardiovascular Research for the UCSF Fresno–Central San Joaquin Valley Medical Education Program and Clinical Professor of Medicine at Stanford University in Palo Alto.

Dr. Deedwania is a Fellow of the American Heart Association (AHA), American College of Cardiology (ACC), American College of Chest Physicians (ACCP), American College of Physicians (ACP), Heart Failure Society of America (HFSA), and European Society of Cardiology (ESC). He has served as Chair of the Executive Committee of the Laennec Society of the AHA and is currently President of the California Chapter of the American Society of Hypertension. Dr. Deedwania is Past President of the International Society for Holter and Noninvasive Electrocardiology (ISHNE). He is a member of several writing groups, including the ACC/AHA Practice Guidelines on Chronic Stable Angina and Ambulatory ECG Monitoring. He also serves on the Practice Guidelines Committee of HFSA. He recently served on the joint writing group of AHA/ADA/ACC for the position statement on intensive glucose control in patients with diabetes. He is currently Chair of the AHA Diabetes Committee and Co-Chair of the ACC Cardio Metabolic working group. He has served as a member of the Annual Scientific Program committees of the ACC, HFSA, and Heart Rhythm Society and is on the annual Scientific Program Committee of the AHA.

Dr. Deedwania has authored numerous landmark clinical trials and has authored or co-authored more than 550 publications, including journal articles, book chapters and abstracts. Dr. Deedwania also serves on the editorial boards of numerous journals. He is an Associate Editor of the Annals of Noninvasive Cardiology, Senior Editor of Congestive Heart Failure, and has served as Guest Editor for the Journal of the American College of Cardiology. Dr. Deedwania lectures regularly both nationally and internationally.

Michael E. Nassif, MD
Assistant Professor of Medicine
Saint Luke’s Mid America Heart Institute
University of Missouri-Kansas City
Kansas City, MO

Michael E. Nassif, MD received his medical degree in 2009 from the University of Iowa. He completed his residency, chief residency, and cardiology and heart-transplant fellowships at Barnes Jewish Hospital/Washington University School of Medicine.

Dr. Nassif also completed a fellowship in cardiovascular outcomes research. He earned his master’s degree in clinical investigation at Saint Luke’s Mid America Heart Institute/University of Missouri-Kansas City, where he now serves as an Assistant Professor of Medicine. Dr. Nassif’s research interests focus on the intersection between diabetes and cardiovascular disease with a specific focus on heart failure.

DISCLOSURE/CONFLICT OF INTEREST STATEMENT

USF Health endorses the standards of the ACCME that require everyone in a position to control the content of an accredited educational activity to disclose all financial relationships with commercial interests that are related to the content of the educational activity. All accredited activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of an accredited educational activity have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

USF Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.

Steering Committee and Program Faculty Disclosures

The steering committee program faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Prakash Deedwania, MD, FACC, FAHA, FACP, FASH, FHFSA, FESC: Advisory Board/Panel: Amgen, Janssen; Consultant: Amgen, Sanofi; Grant/Research Support: Boehringer Ingelheim; Speaker’s Bureau: Janssen

Michael E. Nassif, MD: Nothing to disclose

Non-faculty Content Contributors Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Terry Ann Glauser, MD, MPH; Kathy Merlo; Blair St. Amand; Jaclyn Capazola; Allan Chen, MD: Nothing to disclose

FDA DISCLOSURE

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

SYSTEM REQUIREMENTS

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 80% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test 2 times.

TRANSCRIPT

We are going to point out that really since 2015, there’s been a fundamental paradigm shift in Type 2 diabetes management. We now have two classes of medications, specifically SGLT-2 inhibitors, as well as long-acting, GLP-1 receptor agonist, which improve cardiovascular outcomes, which has now been seen both in multiple randomized, controlled trials as well as real-world data. This has led us to shift our focus from a former hemoglobin A1C and glucose lowering centric point of view to where we are actually able to and we should focus on comprehensive cardiovascular risk reduction. Cardiologists should be at the forefront of this movement. After all, why would cardiologists not be interested in prescribing medications which reduce cardiovascular death? For the full transcript, click here

PROVIDER

Jointly provided by USF Health and Rockpointe

SUPPORTER

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly USA, LLC; and Novo Nordisk, Inc.

Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity